ATE214939T1 - Behandlung von neurologischen zuständen durch eine interleukin-i-inhibierende verbindung - Google Patents

Behandlung von neurologischen zuständen durch eine interleukin-i-inhibierende verbindung

Info

Publication number
ATE214939T1
ATE214939T1 AT92922537T AT92922537T ATE214939T1 AT E214939 T1 ATE214939 T1 AT E214939T1 AT 92922537 T AT92922537 T AT 92922537T AT 92922537 T AT92922537 T AT 92922537T AT E214939 T1 ATE214939 T1 AT E214939T1
Authority
AT
Austria
Prior art keywords
interleukin
treatment
pct
inhibiting compound
neurological conditions
Prior art date
Application number
AT92922537T
Other languages
English (en)
Inventor
Nancy Jane Rothwell
Gareth Roberts
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919123161A external-priority patent/GB9123161D0/en
Priority claimed from GB919125670A external-priority patent/GB9125670D0/en
Application filed by Univ Manchester filed Critical Univ Manchester
Application granted granted Critical
Publication of ATE214939T1 publication Critical patent/ATE214939T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92922537T 1991-10-31 1992-11-02 Behandlung von neurologischen zuständen durch eine interleukin-i-inhibierende verbindung ATE214939T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919123161A GB9123161D0 (en) 1991-10-31 1991-10-31 Treatment of neurological conditions
GB919125670A GB9125670D0 (en) 1991-11-30 1991-11-30 Treatment of neurogical conditions
PCT/GB1992/002023 WO1993008820A1 (en) 1991-10-31 1992-11-02 Treatment of neurological conditions by an interleukin-1 inhibiting compound

Publications (1)

Publication Number Publication Date
ATE214939T1 true ATE214939T1 (de) 2002-04-15

Family

ID=26299779

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92922537T ATE214939T1 (de) 1991-10-31 1992-11-02 Behandlung von neurologischen zuständen durch eine interleukin-i-inhibierende verbindung

Country Status (10)

Country Link
US (1) US6090775A (de)
EP (1) EP0610336B1 (de)
JP (1) JP3623501B2 (de)
AT (1) ATE214939T1 (de)
AU (3) AU2884592A (de)
CA (1) CA2122596C (de)
DE (1) DE69232516T2 (de)
DK (1) DK0610336T3 (de)
ES (1) ES2173871T3 (de)
WO (2) WO1993008820A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
DE69632854T2 (de) * 1995-04-07 2005-07-14 Teijin Ltd. Schutzmittel für Organe und Gewebe
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US20030040660A1 (en) * 2001-08-27 2003-02-27 George Jackowski Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein
WO2003022213A2 (en) * 2001-09-06 2003-03-20 Board Of Regents, The University Of Texas System Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
EA200801166A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
US10117906B2 (en) * 2009-01-09 2018-11-06 The Schepens Eye Research Institute, Inc. Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra
RU2425642C1 (ru) * 2009-12-14 2011-08-10 Государственное образовательное учреждение дополнительного профессионального образования "Иркутский государственный институт усовершенствования врачей Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития постинсультной деменции
ES2952394T3 (es) 2010-07-29 2023-10-31 Buzzard Pharmaceuticals AB Antagonistas quiméricos del receptor IL-1 de tipo I
EP2968468B1 (de) 2013-03-13 2021-07-14 Buzzard Pharmaceuticals AB Chimäre zytokine formulierungen zur okularen verabreichung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
IL100536A (en) * 1986-12-31 1994-05-30 Hoechst Roussel Pharma Pharmaceutical preparations containing a history of xanthine Stopping an immune response and relieving adverse conditions resulting from intracellular intervention in an immune response
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
KR920702606A (ko) * 1989-06-13 1992-10-06 스튜어트 알. 슈터 모노킨(Monokine)의 활성저해
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases

Also Published As

Publication number Publication date
WO1993008819A1 (en) 1993-05-13
AU2884592A (en) 1993-06-07
EP0610336A1 (de) 1994-08-17
JPH07505608A (ja) 1995-06-22
ES2173871T3 (es) 2002-11-01
CA2122596C (en) 2008-06-03
DE69232516D1 (de) 2002-05-02
JP3623501B2 (ja) 2005-02-23
DK0610336T3 (da) 2002-07-22
AU2804192A (en) 1993-06-07
US6090775A (en) 2000-07-18
AU7648296A (en) 1997-02-13
CA2122596A1 (en) 1993-05-13
EP0610336B1 (de) 2002-03-27
DE69232516T2 (de) 2002-10-31
WO1993008820A1 (en) 1993-05-13

Similar Documents

Publication Publication Date Title
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
ATE214939T1 (de) Behandlung von neurologischen zuständen durch eine interleukin-i-inhibierende verbindung
ES2108120T3 (es) Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
DE69934698D1 (de) Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
NO954275D0 (no) Risperidonpamoat
EP0548250A4 (en) Substituted bicyclic aryl compounds exhibiting selective leukotriene b 4? antagonist activity
RU94031161A (ru) Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов
DE69935670D1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
DK0636027T3 (da) Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
DE60225143D1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
TR199701497T1 (xx) Beyin �demini �nleyen terkip.
FR2690847B1 (fr) Compositions a activite agoniste des recepteurs analogues a 5ht1 selective.
ITMI920955A1 (it) Idrogeli di tipo polietereammidoamminico come materiali eparinizzabili
ATE185071T1 (de) Steroide enthaltende zusammensetzungen zur anwendung am auge und ihre verwendung zur behandlung des glaukoms
MX9304075A (es) Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.
ATE141248T1 (de) Neue bis-phenyl-hexene
ES2144452T3 (es) Medicamento para el tratamiento de infecciones protozoarias provocadas por babesia.
KR950032194A (ko) 신규푸린유도체 및 그 약학적으로 허용되는 염
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
NO921525D0 (no) L-alfa-glyserofosforyl-d-myo-inositol for behandling av perifere nervelidelser og hjernelidelser
EP0645963A4 (de)
EP0505389A4 (en) Antiparasitic composition for animal use
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee